Loading...
Loading...
Jefferies is maintaining its rating on AMAG Pharmaceuticals
AMAG.
“We view below-consensus 2011 Feraheme sales guidance as too optimistic and maintain our below-guidance sales estimate,” Jefferies writes. “We remain bearish on Feraheme potential and keep our peak annual sales potential at sub-$100M. With unlikely profitability on Feraheme sales, we maintain Underperform.”
AMAG Pharmaceuticals closed Monday at $16.99.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in